Health Check
Johnson & Johnson has $24 billion in cash with consistent free cash flow generation exceeding $18 billion annually. As one of only two companies with a AAA credit rating (the other is Microsoft), J&J has one of the strongest balance sheets in corporate America.
Revenue grew 5.2% to $88 billion, driven by strong pharmaceutical sales and the MedTech division. The Innovative Medicine segment saw particular strength from oncology and immunology drugs. This is solid, dependable growth for a company this size.
At a P/E ratio of about 16, J&J is priced below the market average of 22. For a company with this level of stability, cash flow, and dividend history, this represents reasonable value. You are paying $16 for every $1 earned.
J&J shares have been on a quiet uptrend, gaining about 7% over three months. The stock trades above its moving averages. It does not have explosive moves like tech stocks, but it consistently grinds higher — exactly what income investors want.
Analysts are generally positive on J&J fundamentals but cautious about ongoing talc litigation settlements. The pharmaceutical pipeline is strong, but generic competition for some key drugs creates uncertainty. Most rate it a hold with a positive bias.
News
J&J Reports Solid Q4, Raises 2026 Guidance
Johnson & Johnson reported Q4 revenue of $23.1 billion, up 5.8% year-over-year, and raised full-year 2026 guidance above consensus. The Innovative Medicine segment grew 7.2%, led by strong sales of Darzalex and Tremfya. The company announced a 4.5% dividend increase — its 63rd consecutive annual increase.
J&J Reaches $8.9 Billion Talc Settlement Agreement
Johnson & Johnson reached a comprehensive settlement agreement to resolve the majority of its talc-related litigation for $8.9 billion paid over 25 years. The settlement, if approved by the courts, would resolve approximately 99% of current claims. Analysts called the resolution "better than feared" and a significant overhang removal for the stock.
FDA Approves J&J's New Lung Cancer Treatment
The FDA granted approval to Johnson & Johnson's new targeted therapy for non-small cell lung cancer, expanding the company's oncology portfolio. Analysts estimate the drug could generate $2-3 billion in peak annual sales. J&J's oncology pipeline is now one of the deepest in the industry.
Financials
Johnson & Johnson generated $88 billion in revenue, growing at a steady 5.2%. For a company this large and this old (founded in 1886), consistent mid-single-digit growth is impressive. The pharmaceutical division drives most of the growth, while MedTech provides stability.
J&J earned $10.65 per share, up 7.1% year-over-year. Profit growth outpaced revenue growth thanks to operational efficiencies and the higher-margin mix of pharmaceutical sales. The company has increased earnings consistently for decades.
J&J generated $22.4 billion in operating cash flow. This consistent cash generation is what funds the company's famously reliable dividend — 63 consecutive years of increases. Very few companies in the world can match this track record.
J&J keeps 69.1 cents of every revenue dollar after production costs. This high margin reflects the value of patented drugs and specialized medical devices — products that are expensive to develop but relatively cheap to manufacture once approved.